Form 4: Pacira BioSciences Chief Medical Officer Reports Routine Tax-Related Stock Transaction

Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc., reported the disposition of 5,084 shares of common stock to cover tax obligations related to a restricted stock unit award vesting.

Summary

• Jonathan Slonin, the Chief Medical Officer of Pacira BioSciences, Inc. (PCRX), filed a Form 4 statement regarding changes in his beneficial ownership.
• On June 3, 2025, Mr. Slonin disposed of 5,084 shares of Pacira BioSciences Common Stock.
• This disposition was a 'F' transaction code, indicating shares withheld by the issuer to cover tax withholding obligations upon the vesting of a restricted stock unit award.
• The shares were valued at $26.4 per share for the purpose of this transaction.
• Following this transaction, Mr. Slonin beneficially owns 181,959.511 shares of Pacira BioSciences Common Stock directly.

Sentiment

Score: 5

Explanation: The document reports a routine, non-discretionary insider transaction (tax withholding upon RSU vesting), which is generally considered neutral in terms of market sentiment.

Positives

• The underlying event, the vesting of a restricted stock unit award, represents a positive equity compensation event for the Chief Medical Officer, indicating continued alignment of management interests with shareholder value.

Negatives

• No direct negatives are associated with this transaction, as it represents a routine tax withholding event rather than a discretionary sale by the insider.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive landscape within the biopharmaceutical sector.

Related Party Transactions

• The transaction involves the disposition of shares by an officer to the issuer for tax withholding purposes, which is a standard process for equity compensation and not typically indicative of unusual related-party dealings.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine administrative transaction related to executive compensation.
• Employees: No direct impact beyond the reporting person.

Key Dates

Keywords

Pacira BioSciences, PCRX, Form 4, Insider Transaction, Jonathan Slonin, Chief Medical Officer, Restricted Stock Units, Equity Compensation, Tax Withholding